Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

[EX Q]: Context: In the county, the population was spread out with 23.20% under the age of 18, 7.70% from 18 to 24, 27.00% from 25 to 44, 28.00% from 45 to 64, and 14.10% who were 65 years of age or older. The median age was 40 years. For every 100 females, there were 97.00 males. For every 100 females age 18 and over, there were 96.40 males. 
 Question: Which age group is smaller: 25 to 44 or 45 to 64?
[EX A]: 25 to 44

[EX Q]: Context: On 1 January 2013, Saint-Germain-sur-l'Arbresle and Nuelles merged becoming one commune called Saint-Germain-Nuelles. 
 Question: What was replaced Saint-Germain-sur-l'Arbresle?
[EX A]: saint-germain-nuelles

[EX Q]: Context: Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant (EGFR(DeltaL747-S752)) or the L858R mutant (EGFR(L858R)) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR(DeltaL747-S752) develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations. 
 Question: Mutations in which gene determine response to both erlotinib and gefitinib?
[EX A]:
epidermal growth factor receptor (egfr) gene